ARVN

Arvinas Inc

7.80

Oct 30 • 2:51 PM ET -0.10 (-1.27%)

Healthcare Biotechnology USA Small NASD

Peers: CCCC GLUE KYMR NRIX OLMA CELC RLAY IDYA ZNTL PFE

| Held by: VTI IWM VXF IWN FESM IBB XPH VTWO SCHA DFAS

Index	RUT
Market Cap	510.01M
Enterprise Value	-49.69M
Income	9.30M
Sales	316.70M
Book/sh	8.61
Cash/sh	8.69
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	246
IPO	Sep 27, 2018

P/E	48.63
Forward P/E	-
PEG	-
P/S	1.61
P/B	0.91
P/C	0.90
P/FCF	-
EV/EBITDA	-
EV/Sales	-0.16
Quick Ratio	7.91
Current Ratio	7.91
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	0.16
EPS next Y	-3.32
EPS next Q	-0.87
EPS this Y	96.43%
EPS next Y	-8053.92%
EPS next 5Y	-
EPS past 3/5Y	40.13% 17.70%
Sales past 3/5Y	25.96% 64.50%
EPS Y/Y TTM	119.57%
Sales Y/Y TTM	-15.05%
EPS Q/Q	407.54%
Sales Q/Q	1014.73%
Earnings	Nov 03 BMO
EPS/Sales Surpr.	789.66% 311.31%

Insider Own	10.38%
Insider Trans	-0.79%
Inst Own	78.95%
Inst Trans	1.62%
ROA	1.17%
ROE	1.59%
ROIC	1.64%
Gross Margin	95.64%
Oper. Margin	-4.01%
Profit Margin	2.94%
SMA20	5.29%
SMA50	-3.70%
SMA200	-19.47%
Trades

Shs Outstand	65.30M
Shs Float	58.60M
Short Float	9.54%
Short Ratio	6.85
Short Interest	5.59M
52W High	14.51 -46.24%
52W Low	6.74 15.73%
Volatility	4.61% 4.63%
ATR (14)	0.35
RSI (14)	53.35
Beta	1.83
Rel Volume	0.58
Avg Volume	816.50K
Volume	394,176

Perf Week	6.85%
Perf Month	4.98%
Perf Quarter	-3.23%
Perf Half Y	-25.78%
Perf YTD	-34.23%
Perf Year	-21.45%
Perf 3Y	-48.28%
Perf 5Y	-90.99%
Perf 10Y	-
Recom	2.31
Target Price	13.93
Prev Close	7.90
Price	7.80
Change %	-1.27%

Consensus

Buy

Avg. Price Target

$13.93

Implied Upside

+78.6%

Analysts14incl. previous ratings

Rating Distribution5 Buy · 8 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 04, 2026	Downgrade	WWells Fargo	Overweight → Equal Weight
Jan 06, 2026	Upgrade	CCitigroup	Neutral → Buy	$15	+92.3%
Oct 15, 2025	Downgrade	GGoldman	Neutral → Sell	$6	-23.1%
Sep 24, 2025	Downgrade	BBofA Securities	Buy → Neutral	$10	+28.2%
Sep 17, 2025	Resumed	BBarclays	Overweight	$16	+105.1%
Jun 02, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform	$9	+15.4%
May 05, 2025	Downgrade	TTruist	Buy → Hold	$11	+41.0%
May 02, 2025	Downgrade	TTD Cowen	Buy → Hold
May 02, 2025	Downgrade	JJefferies	Buy → Hold	$10	+28.2%
Mar 13, 2025	Downgrade	GGoldman	Buy → Neutral	$70 → $15	+92.3%
Mar 12, 2025	Downgrade	WWedbush	Outperform → Neutral	$57 → $12	+53.8%
Mar 11, 2025	Downgrade	OOppenheimer	Outperform → Perform
Dec 10, 2024	Initiated	BBTIG Research	Buy	$69	+784.6%
Nov 18, 2024	Initiated	SStephens	Overweight	$55	+605.1%
Feb 28, 2024	Reiterated	OOppenheimer	Outperform	$95 → $80	+925.6%
Feb 14, 2024	Downgrade	CCitigroup	Buy → Neutral	$36 → $55	+605.1%
Feb 01, 2024	Initiated	GGoldman	Buy	$70	+797.4%
Dec 19, 2023	Upgrade	WWells Fargo	Equal Weight → Overweight	$25 → $63	+707.7%
Dec 06, 2023	Upgrade	JJefferies	Hold → Buy	$40	+412.8%
Nov 20, 2023	Upgrade	GGuggenheim	Neutral → Buy

Oct-27-26 04:01PM	Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation (GlobeNewswire)
12:49PM	After Its Vepinu Windfall, Arvinas Must Show A Thinner Pipeline Can Still Deliver (Earnings Whispers)
07:00AM	Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 (GlobeNewswire)
Oct-15-26 05:30AM	Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs (The Wall Street Journal)
Oct-07-26 07:00AM	Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease (GlobeNewswire)
04:01PM	Loading…
Oct-01-26 04:01PM	Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Sep-29-26 04:01PM	Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-28-26 07:00AM	Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate (GlobeNewswire)
Sep-03-26 04:01PM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-01-26 04:01PM	Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-04-26 07:00AM	Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +11.66%
Aug-03-26 09:30AM	Earnings To Watch: Arvinas Inc (ARVN) Q2 2026 -- GF Value Sees 34% Upside (GuruFocus.com)
Jul-28-26 07:00AM	Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 (GlobeNewswire)
Jun-04-26 08:00AM	Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease (GlobeNewswire)
May-29-26 04:01PM	Arvinas to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
10:30AM	Loading…
May-18-26 10:30AM	Arvinas Employees Give Back During Company-wide Impact Day (GlobeNewswire)
May-12-26 03:01PM	Arvinas Inc (ARVN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Revenue Decline (GuruFocus.com)
08:05AM	Arvinas, Pfizer find new partner for Protac breast cancer drug (BioPharma Dive)
07:05AM	Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) (GlobeNewswire)
May-11-26 09:20AM	What To Expect From Arvinas Inc (ARVN) Q1 2026 Earnings (GuruFocus.com)
May-05-26 07:00AM	Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 (GlobeNewswire)
May-04-26 05:06AM	Protein degraders gain speed as Arvinas scores landmark approval (Pharma Voice)
May-01-26 12:43PM	Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer (GlobeNewswire) +6.16%
12:01PM	Arvinas Protac breast cancer drug cleared by FDA (BioPharma Dive)
Apr-02-26 04:21PM	Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last? (Quartz)
Mar-18-26 07:00AM	Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days (GlobeNewswire) -9.33%
Mar-11-26 07:00AM	Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (GlobeNewswire)
Mar-04-26 10:36AM	Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference (MarketBeat)
Mar-02-26 02:57AM	Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials (Insider Monkey)
02:01PM	Loading…
Feb-24-26 02:01PM	Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges with ... (GuruFocus.com)
10:44AM	Arvinas Q4 Earnings Call Highlights (MarketBeat)
09:40AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-26 07:25AM	Arvinas Inc (ARVN) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-17-26 07:00AM	Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
Feb-12-26 07:00AM	Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director (GlobeNewswire) -9.59%
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire)
Dec-06-25 08:05AM	Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Nov-26-25 07:00AM	Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-24-25 07:00AM	Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)
Nov-05-25 02:02PM	Arvinas Inc (ARVN) Q3 2025 Earnings Call Highlights: Clinical Advancements and Strategic ... (GuruFocus.com)
08:20AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 08:40AM	Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:17AM	Earnings To Watch: Arvinas Inc (ARVN) Reports Q3 2025 Result (GuruFocus.com)
Nov-03-25 04:00PM	Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 07:00AM	Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-24-25 04:00PM	Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-23-25 10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-22-25 04:00PM	Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
10:00AM	Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
09:55AM	Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet (Zacks)
Oct-20-25 04:15AM	Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy (GlobeNewswire)
Oct-13-25 07:00AM	Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Oct-05-25 02:00PM	Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Oct-01-25 07:00AM	Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire) +7.16%
Sep-25-25 09:40AM	Amazon upgraded, Adobe downgraded: Wall Streets top analyst calls (TipRanks)
Sep-24-25 09:36AM	Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Sep-17-25 04:30PM	Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation (GlobeNewswire)
Aug-29-25 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-23-25 04:18AM	Arvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco (Insider Monkey)
Aug-17-25 11:41PM	Arvinas, Pfizer's Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment (Insider Monkey)
Aug-08-25 04:05PM	Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer (GlobeNewswire)
Aug-07-25 10:08AM	Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:04AM	Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
Aug-06-25 12:16PM	Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles (Zacks) -15.51%
11:51AM	BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark (Zacks)
11:48AM	RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down (Zacks)
11:43AM	Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:42AM	ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
08:15AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 12:21PM	ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised (Zacks)
12:12PM	TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line (Zacks)
10:14AM	What To Expect From Arvinas Inc (ARVN) Q2 2025 Earnings (GuruFocus.com)
Aug-01-25 11:49AM	FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
Jul-31-25 10:48AM	Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat (Zacks)
10:37AM	Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
10:15AM	UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y (Zacks)
Jul-30-25 04:05PM	Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
10:23AM	Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales (Zacks)
Jul-24-25 09:10AM	Arvinas, Inc. (ARVN): A Bull Case Theory (Insider Monkey)
Jul-22-25 11:51AM	JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
09:39AM	ALKS Down Despite Positive Top-Line Data From Narcolepsy Study (Zacks)
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks) -5.28%
10:39AM	FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-16-25 11:54AM	Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag (Zacks)
Jul-15-25 10:17AM	Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer (Zacks) -5.97%
Jul-14-25 11:33AM	FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks (Zacks)
Jul-09-25 07:00AM	Arvinas Announces Retirement of Chief Executive Officer and Succession Plan (GlobeNewswire)
Jun-16-25 09:55AM	Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade (Zacks)
Jun-13-25 07:00AM	Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress (GlobeNewswire)
Jun-06-25 07:00AM	Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer (GlobeNewswire) +8.82%
Jun-05-25 08:28AM	Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting (GlobeNewswire)
May-31-25 08:00AM	Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer (GlobeNewswire)
04:00AM	Full Arvinas, Pfizer data confirm potential, limits of Protac drug in breast cancer (BioPharma Dive)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SUNIL AGARWAL	Director	Sep 22 '26	Proposed Sale	8.49	23,105	196,242		Sep 22 04:36 PM
NOAH C BERKOWITZ	Former Officer	Sep 09 '26	Proposed Sale	8.84	37,200	328,915		Sep 09 04:16 PM
NOAH C BERKOWITZ	Former Officer	Sep 04 '26	Proposed Sale	9.45	8,300	78,438		Sep 04 04:23 PM
NOAH C BERKOWITZ	Officer	Aug 04 '26	Proposed Sale	8.80	30,000	264,000		Aug 04 04:13 PM
NOAH C BERKOWITZ	Former Affiliate	Jul 09 '26	Proposed Sale	8.40	24,000	201,528		Jul 09 04:12 PM
Saik Andrew	Chief Financial Officer	Jun 24 '26	Sale	8.16	5,696	46,474	187,432	Jun 24 05:20 PM
Andrew Saik	Officer	Jun 24 '26	Proposed Sale	8.14	5,846	47,586		Jun 23 06:09 PM
Cacace Angela M	Chief Scientific Officer	Jun 17 '26	Sale	7.59	2,576	19,565	180,390	Jun 18 04:06 PM
Angela Cacace	Officer	Jun 17 '26	Proposed Sale	7.42	2,642	19,604		Jun 17 08:59 AM
Teel Randy	President and CEO	May 21 '26	Sale	9.04	2,209	19,962	285,009	May 22 04:15 PM
Randy Teel	Officer	May 21 '26	Proposed Sale	9.10	2,197	19,993		May 20 05:34 PM
Saik Andrew	Chief Financial Officer	May 11 '26	Sale	9.94	11,139	110,693	193,128	May 13 04:18 PM
Loomis David K	VP, Chief Accounting Officer	May 11 '26	Sale	9.94	1,919	19,070	40,193	May 13 04:17 PM
Cacace Angela M	Chief Scientific Officer	May 11 '26	Sale	9.94	9,657	95,965	182,966	May 13 04:16 PM
Berkowitz Noah	Chief Medical Officer	May 11 '26	Sale	9.94	11,108	110,385	191,395	May 13 04:16 PM
Teel Randy	President and CEO	May 11 '26	Sale	9.94	9,657	95,965	287,218	May 13 04:15 PM
Andrew Saik	Officer	May 11 '26	Proposed Sale	10.11	11,343	114,678		May 08 06:06 PM
Angela Cacace	Officer	May 11 '26	Proposed Sale	10.11	9,834	99,422		May 08 06:06 PM
Noah Berkowitz	Officer	May 11 '26	Proposed Sale	10.11	11,312	114,364		May 08 06:05 PM
Randy Teel	Officer	May 11 '26	Proposed Sale	10.11	9,834	99,422		May 08 06:05 PM
Berkowitz Noah	Chief Medical Officer	Mar 18 '26	Sale	11.10	6,435	71,431	202,503	Mar 19 08:01 PM
Noah Berkowitz	Officer	Mar 18 '26	Proposed Sale	12.01	6,022	72,324		Mar 17 07:25 PM
Morrison Briggs	Director	Mar 06 '26	Buy	13.40	20,000	268,070	96,021	Mar 09 04:05 PM
Houston John G	Director	Feb 27 '26	Sale	13.21	35,297	466,154	1,122,183	Mar 02 08:57 PM
John G. Houston	former President and CEO	Feb 27 '26	Proposed Sale	13.21	35,297	466,184		Feb 27 04:02 PM
Loomis David K	Chief Accounting Officer	Feb 23 '26	Sale	12.16	1,108	13,473	29,692	Feb 25 05:09 PM
Cacace Angela M	Chief Scientific Officer	Feb 23 '26	Sale	12.16	3,609	43,885	147,623	Feb 25 05:09 PM
Teel Randy	President and CEO	Feb 23 '26	Sale	12.16	4,786	58,198	149,696	Feb 25 05:08 PM
Angela Cacace	Officer	Feb 23 '26	Proposed Sale	12.16	3,609	43,897		Feb 23 05:55 PM
Randy Teel	Officer	Feb 23 '26	Proposed Sale	12.16	4,786	58,213		Feb 23 05:55 PM
Teel Randy	President and CEO	Feb 13 '26	Sale	11.89	4,403	52,352	154,482	Feb 18 06:16 PM
Saik Andrew	Chief Financial Officer	Feb 13 '26	Sale	11.89	5,134	61,043	159,267	Feb 18 06:14 PM
Cacace Angela M	Chief Scientific Officer	Feb 13 '26	Sale	11.89	4,592	54,599	151,232	Feb 18 06:13 PM
Berkowitz Noah	Chief Medical Officer	Feb 13 '26	Sale	11.89	5,685	67,595	163,938	Feb 18 06:12 PM
Loomis David K	Chief Accounting Officer	Feb 13 '26	Sale	11.89	1,016	12,080	30,800	Feb 18 06:11 PM
Noah Berkowitz	Officer	Feb 13 '26	Proposed Sale	11.89	5,685	67,605		Feb 13 05:00 PM
Angela Cacace	Officer	Feb 13 '26	Proposed Sale	11.89	4,592	54,608		Feb 13 05:00 PM
Randy Teel	Officer	Feb 13 '26	Proposed Sale	11.89	4,403	52,360		Feb 13 04:59 PM
Andrew Saik	Officer	Feb 13 '26	Proposed Sale	11.89	5,134	61,053		Feb 13 04:58 PM
Loomis David K	Chief Accounting Officer	Nov 07 '25	Sale	9.89	230	2,275	31,697	Nov 07 04:20 PM

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

CFO & TreasurerMr. Andrew R. Saik

Chief Scientific OfficerMs. Angela M. Cacace Ph.D.

CEODr. Randy Teel Ph.D.

VP & Chief Accounting OfficerMr. David K. Loomis M.B.A.

Vice President of Investor RelationsMr. Jeff Boyle

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARVN

Arvinas Inc

Upgrade your Finviz experience